Publications by authors named "Y Ohyama"

The Japanese Society of Oral Oncology and Japanese Society of Oral and Maxillofacial Surgeons have jointly developed clinical practice guidelines for oral cancer (oral squamous cell carcinoma) to improve and standardize the quality of oral cancer treatment in Japan. The first, second, and third editions were published in 2009, 2013, and 2019, respectively, and the 2023 edition was recently developed. In the development of the 2023 edition, 60 clinical questions (CQs) were listed.

View Article and Find Full Text PDF

Background: Sjögren's disease (SjD) is an autoimmune disease marked by lymphocytic infiltration of salivary and lacrimal glands, leading to glandular dysfunction, where CD4-positive helper T (Th) cells and their cytokines are crucial in the pathogenesis. Recent studies have demonstrated that Toll-like receptors (TLRs), particularly those recognizing immune complexes containing DNA and RNA, contribute to Th cell activation in various autoimmune diseases. This study explores the expression and function of these TLRs in SjD.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to evaluate the effect of patient transfer slide boards with automatic couch height positioning compensation (AHC) on image quality and radiation dose during computed tomography (CT) examinations.

Methods: The chest phantom for Kyoto Kagaku (Kyoto) Type PBU-SS 2 was performed helical scan using a Canon Medical Systems (Tochigi) 80-row CT Aquilion Prime SP/i Edition. Scan parameters were tube voltage: 120 kV, tube current: min 50 mA max 500 mA with AHC for noise index: 15, slice thickness: 5.

View Article and Find Full Text PDF
Article Synopsis
  • Cases of adenocarcinoma of the uterine cervix (AUC) have worse outcomes than squamous cell carcinoma, and this study examines carbon-ion radiation therapy (CIRT) for AUC through a nationwide Japanese registry in a multicenter prospective approach.
  • The study included 42 patients with locally advanced untreated AUC who received CIRT and cisplatin, aiming to assess 2-year overall survival, local control, and disease-free survival rates, as well as late adverse events (AEs).
  • Results showed a high 2-year overall survival rate of 97.5%, with local control at 80.9% and disease-free survival at 64.3%, indicating that CIRT is a promising treatment
View Article and Find Full Text PDF